Helix BioPharma Corp. (TSE:HBP - Get Free Report) crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$0.93 and traded as high as C$0.98. Helix BioPharma shares last traded at C$0.98, with a volume of 5,000 shares.
Helix BioPharma Stock Performance
The stock has a market cap of C$51.96 million, a P/E ratio of -1.03 and a beta of -0.84. The firm's fifty day moving average is C$0.93 and its 200 day moving average is C$0.96.
Helix BioPharma Company Profile
(
Get Free Report)
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.
See Also
Before you consider Helix BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Helix BioPharma wasn't on the list.
While Helix BioPharma currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
